ARTICLE | Clinical News
Erenumab: Phase III data
October 3, 2016 7:00 AM UTC
Top-line data from the double-blind, international Phase III ARISE (20120297) trial in 577 patients with 4-14 migraine days per month showed that once-monthly 70 mg subcutaneous erenumab for 12 weeks ...